Wolchko J Scott's Form 4 filing
Fate Therapeutics IncFATE · filed Jul 25, 2022
- Accession no.
- 0001209191-22-043143
- Filed
- Jul 25, 2022
- Trade date
- Jul 21-22, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.19M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wolchko J ScottCIK 0001586893 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 21, 2022 | Common Stock | MOption exerciseAcquired | +30,000 | $2.70 | +$81,000 | 461,546 | Direct | |
| Jul 21, 2022 | Common Stock | SSaleDisposed | −10,829 | $32.54F2 | −$352,375.66 | 450,717 | Direct | |
| Jul 21, 2022 | Common Stock | SSaleDisposed | −19,171 | $33.07F3 | −$633,984.97 | 431,546 | Direct | |
| Jul 22, 2022 | Common Stock | MOption exerciseAcquired | +6,246 | $2.70 | +$16,864.2 | 437,792 | Direct | |
| Jul 22, 2022 | Common Stock | SSaleDisposed | −2,923 | $31.33F4 | −$91,577.59 | 434,869 | Direct | |
| Jul 22, 2022 | Common Stock | SSaleDisposed | −2,703 | $32.61F5 | −$88,144.83 | 432,166 | Direct | |
| Jul 22, 2022 | Common Stock | SSaleDisposed | −620 | $33.28F6 | −$20,633.6 | 431,546 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 21, 2022 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 6,246 | Direct | |
| Jul 22, 2022 | Common Stock | MOption exerciseDisposed | −6,246 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold ranging from $31.82 to $32.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold ranging from $32.83 to $33.33 per share.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price of the shares sold ranging from $30.99 to $31.74 per share.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price of the shares sold ranging from $32.02 to $33.01 per share.
Referenced by the price of 1 transaction in Table I.
- F6
Represents the weighted average sale price of the shares sold ranging from $33.03 to $33.67 per share.
Referenced by the price of 1 transaction in Table I.